-
The concurrent conference of the 86th API China exhibition was released, come and talk about the development of the pharmaceutical industry with the big coffee!
Time of Update: 2022-05-05
2 2021 China Pharmaceutical CXO Conference Sub-Forum 4: Frontiers of Pharmaceutical Engineering Forum: From New Drug Development to Scale Manufacturing Meeting Time: May 26 All Day Venue: Room 4, Hall 13.
-
interpack launches a new theme, and the number of exhibition registrations in 2023 has reached 85%
Time of Update: 2022-05-04
As an interpack China exhibition, swop is a grand event for the processing and packaging machinery industry in China and even in Asia, providing customers with a good product and technology display platform .
-
The new situation and new ideas will empower the sustainable development of the green pharmaceutical industry. The first China Green Pharmaceutical Industry Summit will be held in Wuhan!
Time of Update: 2022-05-04
[Pharmaceutical Network Conference Forum] The pharmaceutical industry is both a traditional industry and a strategic emerging industry . Vigorously developing the pharmaceutical industry, creating
-
655 varieties passed the consistency evaluation, and tablets and capsules are still the focus
Time of Update: 2022-05-04
Common problems in pharmacy for consistency evaluation of tablets and capsules include research on impurities of raw materials, particle size research, crystal form research, excipient research, packaging material research, formulation technology research, quality research and stability research, etc.
-
Announcement on the resumption of the 13th Shanghai International Chemical Equipment Expo
Time of Update: 2022-05-04
In order to reduce the impact of the epidemic on the effect of the exhibition, we have focused on strengthening online publicity, promotion and advertising, while deepening media cooperation, and actively communicating and cooperating with relevant chemical industry associations and societies in various provinces and cities.
-
The concurrent meeting of the 87th API China Pharmaceutical Equipment Exhibition is freshly released
Time of Update: 2022-05-04
[Pharmaceutical Network Conference Forum] On October 12-14, 2021, the 87th China International Pharmaceutical API/Intermediate/Packaging/Equipment Fair (API China) will cooperate with the 25th China International Pharmaceutical (Industry) Exhibition The conference and technical exchange meeting (CHINA-PHARM) (←Click to enter the pre-registration channel) will be held at the Wuhan International Expo Center at the same time .
-
On October 12, API China API China & CHINA-PHARM Pharmaceutical Industry Exhibition will meet you in Wuhan!
Time of Update: 2022-05-04
Dear exhibitors, visitors and industry colleagues: The 87th China International Pharmaceutical API/Intermediate/Packaging/Equipment Fair (API China) and the 25th China International Pharmaceutical (Industry) Exhibition and Technology Exchange Conference (CHINA-PHARM) will be held on October 12-14 at Wuhan International Expo Center as scheduled .
-
Protein-degrading drugs and molecular glues account for one-third of the "Drug Hunters" annual list of small molecules
Time of Update: 2022-05-03
Revolution Medicines' KRAS G12C inhibitorRevolution Medicines' KRAS G12C inhibitorImage source: Reference [1]RM-018, developed by Revolution Medicines, is a small molecule inhibitor that inhibits the activity of KRAS G12C mutants by binding to their activated state .
-
Tianmushan Pharmaceutical expects a net profit loss of 30 million yuan to 37 million yuan in 2021
Time of Update: 2022-05-03
It is expected that the net profit attributable to shareholders of listed companies will be 30 million yuan in 2021, a loss of 3.
52 million yuan compared with the same period last year, and a year-on-year loss of 8.
-
Jilin Aodong Holding Subsidiary Obtained 8 National Standard Chinese Medicine Formula Granules Listing Recording Certificates
Time of Update: 2022-05-03
On February 7, Jilin Aodong announced that its holding subsidiary, Yanbian Pharmaceutical, had received 8 national standards for the "Listing Certificate of Traditional Chinese Medicine Formula Granules" .
As of the date of this announcement, it has obtained 99 "Chinese Medicine Formula Granules Listing Recording Certificates" .
-
Fosfomycin tromethamine powder, a subsidiary of Northeast Pharmaceuticals, passed the consistency evaluation of generic drugs
Time of Update: 2022-05-03
On the evening of February 10, Northeast Pharmaceuticals announced that its wholly-owned subsidiary, No.
It has passed the consistency evaluation of generic drugs .
Fosfomycin tromethamine powder is suitable for the treatment of acute simple urinary tract infection caused by sensitive Escherichia coli, Enterococcus faecalis, Klebsiella pneumoniae, Citrobacter, Enterobacter, and Proteus mirabilis etc.
-
Buchang Pharmaceutical cancels its wholly-owned subsidiary Zhongxin Shunfa
Time of Update: 2022-05-03
The above matters have been completed, and the company has recently received the "Notice of Deregistration of Foreign-invested Enterprises" issued by Xianyang Market Supervision and Administration Bureau .
-
Eli Lilly's dual agonist tirzepatide has no obvious advantage over competitor drugs!
Time of Update: 2022-05-03
While ICER reviewers said tirzepatide had a clear benefit over background therapy, experts were divided over the drug's benefit over Novo Nordisk Ozempic and Eli Lilly/Boehringer Ingelheim Jardiance .
-
The Role of the Oncology Drug Advisory Committee (ODAC) in FDA Review
Time of Update: 2022-05-03
What kind of organization is ODAC, and how much influence will it have on the FDA's review results?introduction:Picture from: US FDA official websiteAC and ODACAC and ODACOrganizational Structure and Main ResponsibilitiesOrganizational Structure and Main ResponsibilitiesThere are many disciplines involved in drug regulation, and with the acceleration of information updates, the regulatory authorities will also appear powerless .
-
Mycoplasma pneumoniae pneumonia treatment: which drug is azithromycin relegated to the second line of choice?
Time of Update: 2022-05-03
From the "Guidelines for the Diagnosis and Treatment of Community-Acquired Pneumonia in Chinese Adults (2016 Edition)" [2], azithromycin (and clarithromycin) have taken a back seat in the treatment of Mycoplasma pneumoniae pneumonia, replaced by doxycycline, mino Cyclic or respiratory quinolones, and macrolides in areas with low rates of mycoplasma resistance .
-
Jiu'an Medical received the decision on administrative supervision measures, the chairman and the secretary were interviewed
Time of Update: 2022-05-03
On the evening of February 14, Jiu'an Medical announced that the company recently received a "Decision on Administrative Supervision Measures" ( Hereinafter referred to as the "Decision"), "Decision on Taking Regulatory Talk Measures against Liu Yi and Wu Tong" (Jin Zheng Jian Measures [2022] No.
-
Tianmushan Pharmaceutical elected Li Feng as chairman and Liu Bo as vice chairman
Time of Update: 2022-05-03
Zhang Yingjun as a supervisor for a term of office from the date of approval at the general meeting of shareholders to the expiration of the eleventh session of the Supervisory Committee .
-
The world's first freeze-dried mRNA vaccine preclinical data release How is the progress of mRNA vaccine at home and abroad?
Time of Update: 2022-05-03
According to the 221-year financial report released by Pfizer earlier, the total revenue of the new crown vaccine Comirnaty reached 36.
Fosun Pharma's 2021 mid-year financial report shows that Fosun Pharma/German BioNTech's mRNA new crown vaccine Fubitai® (BNT162b2) achieved revenue of more than 500 million yuan in Hong Kong and Macau in the first half of 2021 .
-
Memantine Hydrochloride Sustained-Release Capsules, a subsidiary of Renfu Pharmaceutical Holdings Limited, obtained the drug registration certificate
Time of Update: 2022-05-03
com, in 2020, the sales of all formulations of memantine in the three major terminal public hospitals of cities, counties and townships in China will be approximately RMB 600 million.
-
GSK Belimumab Approved in China for Systemic Lupus and Active Lupus Nephritis in Adults
Time of Update: 2022-05-03
In China, belimumab was approved for marketing through priority review in July 2019, and is suitable for active, autoantibody-positive adult patients with systemic lupus erythematosus who still have high disease activity on the basis of conventional treatment .
